Latest Content

Cemiplimab plus chemotherapy produced variable outcomes by genomic profile in patients with nonsquamous NSCLC.

Neil Mendhiratta, MD, MS, discusses the treatment landscape for patients with kidney cancer during Kidney Cancer Awareness Month.

Lurbinectedin plus atezolizumab received CHMP recommendation as first-line maintenance for ES-SCLC that has not progressed following induction therapy.

An NDA for lirafugratinib in pretreated, FGFR2-altered cholangiocarcinoma was accepted for FDA review and assigned a PDUFA date of September 27, 2026.

6-year Roswell Park study shows shorter, lower-dose approach works just as well as longer course of treatment

The biosimilar Ponlimsi is approved for all reference denosumab indications, and applications for an omalizumab biosimilar candidate have been accepted.

Michael J. Mauro, MD, discusses the variety of TKIs available for chronic myeloid leukemia management and how to navigate new formulations.

We recap the top regulatory decisions of March in GI malignancies.

Erda-iDRS was safe and produced early efficacy signals in FGFR-altered NMIBC.

Enolen was safe and feasible for the treatment of patients with early-stage prostate cancer.

The FDA cleared relacorilant plus nab-paclitaxel in ovarian cancer, the primary end point of the SENTRY trial in myelofibrosis was met, and more.

Gotistobart improved response rates and overall survival vs docetaxel in pretreated squamous NSCLC in stage 1 of the PRESERVE-003 trial.

The EMA's CHMP recommends marketing authorization for tarlatamab monotherapy for ES-SCLC following relapse during or after platinum-based chemotherapy.